$DYN

Dyne Therapeutics, Inc.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapeutics for people with genetically driven neuromuscular diseases. Its FORCE platform uses an antibody fragment that binds to transferrin receptor 1, a linker and a therapeutic payload to deliver treatments to muscle tissue and potentially the central nervous system. Payloads include oligonucleotides and enzymes. Dyne’s programs target Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy and Pompe disease. Its lead candidates, z-rostudirsen for DMD and z-basivarsen for DM1, are in global Phase 1/2 trials. The company also has DMD candidates for additional exon-skipping targets in development and is advancing FSHD and Pompe programs. Dyne makes money through products and programs in its pipeline; it has global commercial rights to all its programs. Dyne is headquartered in Waltham, Massachusetts.

AlphAI earnings readsecond quarter of 2026 · JUL 29Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $DYN in the last 7 days.

—
$174K
Friedl-Naderer Johanna
100%
See all $DYN insider activity →
Med

Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Dyne Therapeutics (DYN) reported a wider Q3 2026 net loss of $193.6M ($1.06 per share) due to higher R&D and administrative expenses. Cash reserves are $1.134B, expected to last into Q2 2028. The company's z-rostudirsen BLA is under FDA priority review, with a PDUFA date of January 21, 2027. Topline ACHIEVE trial data for z-basivarsen are expected in Q1 2027. DYN stock is trading at $18.23, down 1.78%.

Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 20

Why Dyne Therapeutics (DYN) Is Back In The Spotlight

Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.

DYN sentiment & insider activity

Recent DYN coverage spans market movers, earnings and technology.

In the last 30 days, DYN insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($174K). The most active reporter was Friedl-Naderer Johanna, Chief Commercial Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving DYN

AlphAI scores every news story that mentions DYN with an AI model for sentiment and relevance, and aggregates insider trades from Dyne Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $DYN

Score

Dyne Therapeutics Q3 Loss Widens On Higher R&D Costs; Cash Runway Extends Into Q2 2028

Dyne Therapeutics (DYN) reported a wider Q3 2026 net loss of $193.6M ($1.06 per share) due to higher R&D and administrative expenses. Cash reserves are $1.134B, expected to last into Q2 2028. The company's z-rostudirsen BLA is under FDA priority review, with a PDUFA date of January 21, 2027. Topline ACHIEVE trial data for z-basivarsen are expected in Q1 2027. DYN stock is trading at $18.23, down 1.78%.

$DYNMedEarnings

Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 20

Why Dyne Therapeutics (DYN) Is Back In The Spotlight

Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.

$DYNMedAI 9/10Clinical / regulatory· topline data

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

Dyne Therapeutics (DYN) reported 12-month data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1, showing functional improvements across multiple measures. The company expects topline data from the registrational expansion cohort in Q1 2027, with a potential U.S. Accelerated Approval submission in Q3 2027. The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds.

Dyne Therapeutics Tumbles As Hot-Streak Rally Cools

Dyne Therapeutics (DYN) shares fell after a recent rally driven by positive clinical data and a competitor's trial failure. Investors are taking profits, but the company's low debt and cash runway until 2028 provide financial flexibility. Risks include cash burn, no approved products, and dependence on future financing.

$DYNHighAI 9/10

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.

Stocks and Bonds Fall as Crude Oil Surges

Global markets are mixed, with stocks and bonds falling as crude oil surges. The 10-year T-note yield rose to a 2.75-year high of 4.849%. Chipmakers and energy producers gained, while ServiceTitan (TTAN) fell over 30% after a larger-than-expected Q2 loss. Casys General Stores (CASY) dropped 14% due to a lower-than-expected Q1 gross margin. Meta Platforms (META) rose 6% on positive AI assistant reviews.

Related tickers